AMAG Pharmaceuticals under Investigation for
Potentially Defrauding Shareholders, Says Hagens
March 24, 2010 10:43 PM Eastern Daylight Time
SEATTLE--(EON: Enhanced Online News)--Hagens Berman Sobol Shapiro LLP announced today it has begun an
investigation of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for potentially misrepresenting information to
shareholders which may have artificially increased stock values. Hagens Berman believes the biopharmaceutical giant
violated federal securities laws, specifically the Securities Exchange Act which protects the rights of shareholders.
AMAG Pharmaceuticals may have withheld information pertaining to the company’s primary drug, Feraheme, in the
Registration Statement issued on Jan. 21, 2010. More than 3.6 million shares of AMAG common stock sold to the
public at a potentially inflated price of $48.25 per share, the law firm believes, thereby raising more than $173 million
from its initial public offering.
In mid-February, AMAG's stock fell over $7.00 to close at $38.12 per share after analyst reports indicated that
several patients exposed to Feraheme experienced serious adverse reactions and possibly one death.
The law firm believes AMAG’s stock values declined further after reports claimed the company failed to disclose the
IPO strategy behind a rebate program. The company might have attempted to front load sales into the fourth quarter
which would cause sales to drop off after the initial offering.
If you have information related to AMAG’s failure to disclose adverse reactions to Feraheme in the Registration
Statement, you are encouraged to contact attorneys at Hagens Berman at AMAG@hbsslaw.com or to call at 510-
Investors who purchased shares of AMAG between Jan. 21, 2010 and March 1, 2010 can move for lead plaintiff
but must do so on or before May 18, 2010. To discuss moving for lead plaintiff please contact Peter Borkon at
510-725-3030 or email him at AMAG@hbsslaw.com.
About Hagens Berman
Hagens Berman Sobol Shapiro LL